The FDA approval and launch of CASGEVY, a gene therapy for treating ... reaching key milestones such as generating continued growth in vial demand for SYFOVRE. Commercial vial demand for SYFOVRE ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...

With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly evolving ...

With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...